文献速递泌尿男性生殖肿瘤

帕博利珠单抗联合仑伐替尼加贝组替凡或quavonlimab一线治疗晚期肾细胞癌:LITESPARK-012随机对照3期研究

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
PubMed 文献 · Ann Oncol · 2026-10-25

LITESPARK-012研究纳入初治晚期透明细胞肾细胞癌成人患者,随机分配至帕博利珠单抗+仑伐替尼+贝组替凡(A组)、quavonlimab/帕博利珠单抗+仑伐替尼(B组)或标准治疗帕博利珠单抗+仑伐替尼(对照组)。结果显示,在帕博利珠单抗+仑伐替尼基础上加用贝组替凡或quavonlimab均未改善无进展生存期或总生存期,且研究组因不良事件停药率更高。

要点

  • 在帕博利珠单抗+仑伐替尼基础上加用贝组替凡或quavonlimab未改善PFS或OS。
  • A组和B组因不良事件导致任何药物停药的比例分别为51.6%和51.4%,高于对照组的36.2%。
  • 标准治疗帕博利珠单抗+仑伐替尼的疗效与安全性与既往报告一致。

核心结论

  • 对于初治晚期肾细胞癌患者,在帕博利珠单抗联合仑伐替尼基础上加用HIF-2α抑制剂贝组替凡或CTLA-4抑制剂quavonlimab,均未较帕博利珠单抗联合仑伐替尼单用改善结局。
  • 研究组因不良事件导致的停药率高于对照组。

研究设计与样本

  • 随机、开放标签、3期研究(LITESPARK-012,NCT04736706),纳入初治晚期透明细胞肾细胞癌成人患者。
  • 按1:1:1随机分配至A组(帕博利珠单抗400 mg IV Q6W+仑伐替尼20 mg口服每日+贝组替凡120 mg口服每日)、B组(quavonlimab/帕博利珠单抗25 mg/400 mg IV Q6W+仑伐替尼)或对照组(帕博利珠单抗+仑伐替尼)。
  • 共560例分配至A组,562例至B组,566例至对照组;截至2026年2月4日数据截止,中位随访43.6个月(范围31.8-57.4)。

主要发现

  • 全体人群中,A组中位PFS为20.8个月(vs对照HR 1.08,95%CI 0.93-1.26;P=0.8408),B组为20.7个月(vs对照HR 1.07,95%CI 0.92-1.25;名义P=0.8174),对照组为23.7个月。
  • 全体人群中,A组中位OS为52.0个月(vs对照HR 1.04,95%CI 0.87-1.25;P=0.6622),B组未达到(vs对照HR 1.12,95%CI 0.94-1.35;名义P=0.8955),对照组未达到。
  • IMDC中/高风险人群中,B组中位PFS为20.5个月,对照组为23.5个月(HR 1.12,95%CI 0.94-1.33;P=0.8954);中位OS分别为39.1个月和46.2个月(HR 1.17,95%CI 0.96-1.42;P=0.9419)。
  • 任何级别全因不良事件导致任何药物停药的比例在A、B、对照组分别为51.6%、51.4%、36.2%。

临床怎么用

  • 结果不支持在帕博利珠单抗联合仑伐替尼一线治疗晚期肾细胞癌的基础上常规加用贝组替凡或quavonlimab。
  • 帕博利珠单抗联合仑伐替尼仍是晚期透明细胞肾细胞癌的一线标准治疗选择之一,其疗效与安全性与既往报告一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen. PARTICIPANTS AND METHODS: Adults with previously untreated advanced ccRCC were randomized 1:1:1 to 400 mg pembrolizumab IV Q6W plus 20 mg lenvatinib orally daily and 120 mg belzutifan orally daily (Arm A); coformulated quavonlimab/pembrolizumab 25 mg/400 mg IV Q6W (collectively called MK-1308A) plus lenvatinib (Arm B); or standard-of-care pembrolizumab plus lenvatinib (Control). Treatment continued until progression, unacceptable toxicity, or withdrawal from study; pembrolizumab or quavonlimab/pembrolizumab were administered for a maximum of ∼2 years. Progression-free survival (PFS) by blinded independent central review and overall survival (OS) were dual primary endpoints, tested in all randomized participants for Arm A versus Control, and in participants with IMDC intermediate/poor risk or all participants for Arm B versus Control. Safety was a secondary endpoint. RESULTS: Overall, 560 participants were randomized to Arm A, 562 to Arm B, and 566 to Control. As of the data cutoff date (February 4, 2026), median follow-up was 43.6 months (range, 31.8-57.4). Among all participants, median PFS was 20.8 months in Arm A (HR vs Control: 1.08, 95%CI 0.93-1.26; P=0.8408), 20.7 months in Arm B (HR vs Control: 1.07, 95%CI 0.92-1.25; nominal P=0.8174), and 23.7 months in the Control arm; median OS was 52.0 months in Arm A (HR vs Control: 1.04, 95%CI 0.87-1.25; P=0.6622), not reached (NR) in Arm B (HR vs Control: 1.12, 95%CI 0.94-1.35; nominal P=0.8955), and NR in the Control arm. Among participants with intermediate/poor risk, median PFS was 20.5 months in Arm B and 23.5 months in the Control arm (HR 1.12, 95%CI 0.94-1.33; P=0.8954); median OS was 39.1 versus 46.2 months (HR 1.17, 95%CI 0.96-1.42; P=0.9419). Any-grade all-cause adverse events led to any-drug discontinuation in 51.6%, 51.4%, and 36.2% of participants in the A, B, and Control arms. CONCLUSIONS: Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone. Higher drug discontinuation rates due to adverse events occurred in the investigational arms. Efficacy and safety of standard-of-care pembrolizumab plus lenvatinib was consistent with prior reports.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rini BI, Choueiri TK, Voss MH, et al. Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. Ann Oncol. 2026. PMID: 42927856. doi:10.1016/j.annonc.2026.10.1281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。